Filgrastim (Neupogen, Nivestym, Zarxio, Releuko)_Non-oncology

Filgrastim is covered only for specified non‑oncology indications — symptomatic severe chronic neutropenias (congenital, cyclic, idiopathic), HIV/AIDS‑associated neutropenia, and drug‑induced (non‑chemotherapy) agranulocytosis/neutropenia — while oncology/chemotherapy uses are excluded. Approvals are time‑limited (up to 6 months for severe chronic neutropenia, 4 months for HIV‑related neutropenia, 1 month for drug‑induced), require prescribing by or documented consultation with the appropriate specialist (hematologist; infectious disease/hematology/HIV specialist for HIV cases), must meet dosing limits (≤12 mcg/kg/day for severe chronic neutropenia; ≤10 mcg/kg/day for HIV/drug‑induced), and require documentation of diagnosis, symptoms (where required), weight, and intended duration.

"Chronic administration to reduce the incidence and duration of sequelae of neutropenia (e."